Performance of urine samples compared to cervical samples for detection of precancer lesions among HPV-positive women attending colposcopy clinic in Mexico City.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Causes & Control Pub Date : 2024-06-01 Epub Date: 2024-02-18 DOI:10.1007/s10552-024-01852-w

Joacim Meneses-León, Sonia Hernández-Salazar, Leticia Torres-Ibarra, Rubí Hernández-López, Berenice Rivera-Paredez, Karina Robles-Rivera, Eduardo Lazcano-Ponce, Alba García-Vera, Mélany Godínez-Pérez, Leith León-Maldonado, Jorge Salmerón

{"title":"Performance of urine samples compared to cervical samples for detection of precancer lesions among HPV-positive women attending colposcopy clinic in Mexico City.","authors":"Joacim Meneses-León, Sonia Hernández-Salazar, Leticia Torres-Ibarra, Rubí Hernández-López, Berenice Rivera-Paredez, Karina Robles-Rivera, Eduardo Lazcano-Ponce, Alba García-Vera, Mélany Godínez-Pérez, Leith León-Maldonado, Jorge Salmerón","doi":"10.1007/s10552-024-01852-w","DOIUrl":null,"url":null,"abstract":"Background: High-risk human papillomavirus (hrHPV) detection in self-collected urine samples (SeCUS) may be a promising alternative for cervical cancer screening because of its greater acceptability, as long as it can offer comparable sensitivity to clinician-collected cervical samples (CCoS) for detecting precancer lesions.Objective: To evaluate the performance of the SeCUS compared to that of the CCoS for cervical intraepithelial neoplasia grade 3 (CIN3) detection among hrHPV-positive women receiving colposcopy in Mexico City using different specific extended HPV typing procedures: HPV16/18, HPV16/18/35/39/68 or HPV16/18/35/39/68/31.Methods: From March 2017 to August 2018, 4,158 female users of the cervical cancer screening program at Tlalpan Sanitary Jurisdiction in Mexico City were invited to participate in the FRIDA-Tlalpan study. All participants provided ≥ 30 mL of SeCUS, and then a CCoS was obtained with Cervex-Brush®, which was used for hrHPV typing. Participants who tested positive for hrHPV in CCoS were referred for colposcopy for diagnostic confirmation, and all SeCUS of these women were also tested for hrHPV typing.Results: In total, 561 hrHPV-positive women were identified by CCoS via colposcopy, and 82.2% of the SeCUS of these women were also hrHPV positive. From both CCoS and SeCUS, 7 cases of CIN3 were detected. Considering HPV16/18 typing, CCoS and SeCUS detected 4 cases of CIN3, but after HPV16/18/35/39/68/31 extension typing, both CCoS and SeCUS detected all 7 of the CIN3 cases among the hrHPV-positive women.Conclusions: Using extended hrHPV typing based on HPV16/18/35/39/68/31, our results suggest that the performance of SeCUS may be equivalent to that of CCoS for detecting CIN3 lesions. Although our results are inconclusive, they support the hypothesis that SeCUS may be an attractive alternative worthy of further research.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"935-942"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129980/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Causes & Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10552-024-01852-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: High-risk human papillomavirus (hrHPV) detection in self-collected urine samples (SeCUS) may be a promising alternative for cervical cancer screening because of its greater acceptability, as long as it can offer comparable sensitivity to clinician-collected cervical samples (CCoS) for detecting precancer lesions.

Objective: To evaluate the performance of the SeCUS compared to that of the CCoS for cervical intraepithelial neoplasia grade 3 (CIN3) detection among hrHPV-positive women receiving colposcopy in Mexico City using different specific extended HPV typing procedures: HPV16/18, HPV16/18/35/39/68 or HPV16/18/35/39/68/31.

Methods: From March 2017 to August 2018, 4,158 female users of the cervical cancer screening program at Tlalpan Sanitary Jurisdiction in Mexico City were invited to participate in the FRIDA-Tlalpan study. All participants provided ≥ 30 mL of SeCUS, and then a CCoS was obtained with Cervex-Brush®, which was used for hrHPV typing. Participants who tested positive for hrHPV in CCoS were referred for colposcopy for diagnostic confirmation, and all SeCUS of these women were also tested for hrHPV typing.

Results: In total, 561 hrHPV-positive women were identified by CCoS via colposcopy, and 82.2% of the SeCUS of these women were also hrHPV positive. From both CCoS and SeCUS, 7 cases of CIN3 were detected. Considering HPV16/18 typing, CCoS and SeCUS detected 4 cases of CIN3, but after HPV16/18/35/39/68/31 extension typing, both CCoS and SeCUS detected all 7 of the CIN3 cases among the hrHPV-positive women.

Conclusions: Using extended hrHPV typing based on HPV16/18/35/39/68/31, our results suggest that the performance of SeCUS may be equivalent to that of CCoS for detecting CIN3 lesions. Although our results are inconclusive, they support the hypothesis that SeCUS may be an attractive alternative worthy of further research.

Abstract Image

查看原文本刊更多论文

在墨西哥城接受阴道镜检查的 HPV 阳性妇女中，尿液样本与宫颈样本在检测癌前病变方面的性能比较。

背景：在自采尿液样本（SeCUS）中检测高危人乳头状瘤病毒（hrHPV）可能是宫颈癌筛查的一种有前途的替代方法，因为它具有更高的可接受性，只要它在检测癌前病变方面具有与临床医生采集的宫颈样本（CCoS）相当的灵敏度：在墨西哥城接受阴道镜检查的 hrHPV 阳性妇女中，使用不同的特定扩展 HPV 分型程序，评估 SeCUS 与 CCoS 检测宫颈上皮内瘤变 3 级（CIN3）的性能比较：HPV16/18、HPV16/18/35/39/68或HPV16/18/35/39/68/31.方法：2017年3月至2018年8月，墨西哥城特拉尔潘卫生辖区的4158名宫颈癌筛查项目女性用户受邀参加了FRIDA-特拉尔潘研究。所有参与者都提供了 ≥ 30 mL 的 SeCUS，然后用 Cervex-Brush® 采集了 CCoS，用于 hrHPV 分型。在 CCoS 中检测出 hrHPV 阳性的参与者将被转诊至阴道镜进行确诊，这些妇女的所有 SeCUS 也将进行 hrHPV 分型检测：结果：通过阴道镜检查，CCoS 共发现 561 名 hrHPV 阳性女性，其中 82.2% 的 SeCUS 也为 hrHPV 阳性。从 CCoS 和 SeCUS 中均检测出 7 例 CIN3。考虑到HPV16/18分型，CCoS和SeCUS检测出4例CIN3，但在HPV16/18/35/39/68/31扩展分型后，CCoS和SeCUS在hrHPV阳性妇女中检测出全部7例CIN3：结论：使用基于 HPV16/18/35/39/68/31 的 hrHPV 扩展分型，我们的结果表明 SeCUS 检测 CIN3 病变的性能可能与 CCoS 相当。尽管我们的结果还不确定，但它们支持了 SeCUS 可能是一种有吸引力的替代方法的假设，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Causes & Control 医学-公共卫生、环境卫生与职业卫生

CiteScore

3.90

自引率

4.30%

发文量

130

审稿时长

6.6 months

期刊介绍： Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. By drawing together related information published currently in a diverse range of biological and medical journals, it has a multidisciplinary and multinational approach. The scope of the journal includes: variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues. The emphasis is on speed of publication. The journal will normally publish within 30 to 60 days of acceptance of manuscripts. Cancer Causes & Control publishes Original Articles, Reviews, Commentaries, Opinions, Short Communications and Letters to the Editor which will have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also contains significant information for government agencies concerned with cancer research, control and policy.